Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00481754 · ClinicalTrials.gov registry record

Benign Reproductive Tissue Analysis for Endometrial Cancer Markers

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
359
Enrollment target

NCT00481754: Completed study, sponsored by National Cancer Institute (NCI).

NCT00481754 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 359 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00481754 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
359 participants
Enrollment target

Study Summary

Background: * Endometrial cancer (cancer of the lining of the uterus) is the most common gynecologic cancer in the United States. * Currently, there are no markers (components of blood and tissue that determine who might be at risk for developing cancer) for endometrial cancer. Objectives: -To see if women who are undergoing hysterectomy are willing to provide blood and tissue samples to help doctors identify markers that would indicate increased risk for developing endometrial cancer. Eligibility: -Women between 35 and 54 years of age who will undergo hysterectomy for a non-cancerous condition, such as uterine fibroids, uterine prolapse, abnormal uterine bleeding, and others at Magee-Women's Hospital in Pittsburgh, Penn. Design: * Patients' medical records are reviewed and patients complete a questionnaire including information on race and ethnic background, education, marital status, family history, height, weight, pregnancy history, smoking history, medication history, history about menstrual periods and menopausal symptoms. * Patients provide blood and urine samples before surgery. * A sample of fat tissue is removed during surgery in patients undergoing abdominal surgery. * Tissue samples from the removed uterus (and ovaries if the ovaries are also removed) are collected and analyzed for markers for endometrial cancer.

Trial Details

FieldValue
Enrollment Target 359 participants
Start Date 2006-04-24
Est. Completion 2020-11-13

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00481754

The ClinicalTrials.gov registry entry for NCT00481754 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00481754 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00481754 about?

NCT00481754 is a clinical study titled "Benign Reproductive Tissue Analysis for Endometrial Cancer Markers". Background: * Endometrial cancer (cancer of the lining of the uterus) is the most common gynecologic cancer in the United States. * Currently, there are no markers (components of blood and tissue that determine who might be at risk for developing cancer) for endometrial cancer. Objectives: -To se...

What is the current status of trial NCT00481754?

This trial is currently completed. The enrollment target is 359 participants. The study started on 2006-04-24. Estimated completion is 2020-11-13.

Who is sponsoring clinical trial NCT00481754?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.